News

Filter

Current filters:

BayerDiabetes

151 to 160 of 97213 results

Official: Merck & Co to acquire Cubist for $8.4 billion

Official: Merck & Co to acquire Cubist for $8.4 billion

08-12-2014

Confirming weekend speculation and rumors, US pharma giant Merck & Co this morning said it has entered…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsZerbaxa

FDA approves new indication for Amgen's Xgeva

FDA approves new indication for Amgen's Xgeva

08-12-2014

USA-based Amgen says the US Food and Drug Administration has approved a new indication for Xgeva (denosumab),…

AmgenBiotechnologyOncologyRare diseasesRegulationUSAXgeva

EFPIA responds to European Commission's patent settlement report with own transparency proposal

EFPIA responds to European Commission's patent settlement report with own transparency proposal

08-12-2014

The European Commission has published its fifth Monitoring Report of Patent Settlements in the pharma…

EuropeEuropean CommissionLegalPharmaceuticalRegulation

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

08-12-2014

The Scottish Medicines Consortium has decided to grant access to Gazyvaro (obinutuzumab), manufactured…

AdempasBayerCardio-vascularGazyvaroOncologyPharmaceuticalRegulationRoche

A top-20 pharma to utilize Xyntek-Antares serializing for China

A top-20 pharma to utilize Xyntek-Antares serializing for China

08-12-2014

A top 20 multi-national pharmaceutical research and manufacturer is utilizing the Xyntek-Antares solution…

ChinaPharmaceuticalProductionRegulationXyntek

Spanish government should consider linking pharmaceutical spending to GDP growth

Spanish government should consider linking pharmaceutical spending to GDP growth

08-12-2014

Pharmaceutical spending has fallen nearly 30% in Spain in last four years. According to IMS Health data,…

FinancialPharmaceuticalPoliticsPricingSpain

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

Latest Ph III data for UCB’s brivaracetam presented at AES

Latest Ph III data for UCB’s brivaracetam presented at AES

08-12-2014

Positive primary efficacy and safety data from the latest Phase III study evaluating Belgian drugmaker…

BRIVARACETAMNeurologicalPharmaceuticalResearchUCB

Labeling update of Lundbeck and Otsuka’s Abilify Maintena approved by FDA

08-12-2014

The US Food and Drug Administration approved the labeling update of Abilify Maintena (aripiprazole) for…

Abilify MaintenaLundbeckNeurologicalOtsuka PharmaceuticalPharmaceuticalRegulationUSA

151 to 160 of 97213 results

Back to top